Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly

Author(s):
Strasburger, C.J.; Karavitaki, N.; Stormann, S.; Trainer, P.J.; Kreitschmann-Andermahr, I.; Droste, M.; Korbonits, M.; Feldmann, B.; Zopf, K.; Sanderson, V.F.; Schwicker, D.; Gelbaum, D.; Haviv, A.; Bidlingmaier, M.; Biermasz, N.R. (0000-0001-5817-3594)
Published
2016
Publication type
Article / Letter to editor

Abstract

Conclusion: Lifelong injections of long-acting somatostatin analogues have significant burden on the functioning, well-being and daily lives of patients with acromegaly.

Date issued
2016-03-01
Language
English
Publisher
BIOSCIENTIFICA LTD
Is part of
European Journal of Endocrinology (2016), Vol. 174, no. 3, p. 355-362
hdl
1887/99417
doi
10.1530/EJE-15-1042